<DOC>
	<DOCNO>NCT02343120</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , pharmacokinetic profile treatment effect new drug know BGB-3111 patient B-Cell Lymphoid Malignancies .</brief_summary>
	<brief_title>Study Safety Pharmacokinetics BGB-3111 Subjects With B-Cell Lymphoid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1 . Aged ≥ 18 year , voluntarily consent study . 2. WHO classification define Blymphoid malignancy , exception Burkitt lymphoma/leukemia , plasma cell myeloma , acute lymphoblastic leukemia , lymphoblastic lymphoma , plasmablastic lymphoma . 3 . Requirement treatment opinion investigator . 4 . Disease relapse , refractory , follow least one line therapy , therapy high priority available . 5 . ECOG performance status 02 . 6 . Adequate hematologic function , define neutrophil ≥ 1.0 x 10^9/L platelet ≥ 50 x 10^9/L ; patient neutrophils &lt; 1.0 x 10^9/L due marrow infiltration allow receive growth factor bring pretreatment neutrophil ≥ 1.0 x 10^9/L . 7 . Adequate renal function , define creatinine clearance ≥ 50 ml/min ( estimate CockcroftGault equation measure nuclear medicine scan 24 hour urine collection ) . 8 . Adequate liver function , define AST ALT ≤ 3 x ULN , bilirubin ≤ 1.5 x ULN ( unless document Gilbert 's syndrome ) . 9 . INR APTT ≤ 1.5 x ULN . 10 . Female subject childbearing potential nonsterile male must practice least one follow method birth control partner ( ) throughout study 90 day discontinue study drug : total abstinence sexual intercourse , doublebarrier contraception , IUD hormonal contraceptive initiate least 3 month prior first dose study drug . 11 . Male subject must donate sperm initial study drug administration , 90 day drug discontinuation . 1 . Current CNS involvement disease 2 . Current histologically transform disease . 3 . Prior BTK inhibitor treatment . 4 . Allogeneic stem cell transplantation within 6 month , active GVHD require ongoing immunosuppression . 5 . Receipt follow treatment prior first dose BGB3111 : corticosteroid give antineoplastic intent within 7 day , chemotherapy radiotherapy within 2 week , monoclonal antibody within 4 week . 6 . Not recovered toxicity prior chemotherapy grade ≤ 1 . 7 . History active malignancy within 2 year study entry , exception ( 1 ) adequately treat insitu carcinoma cervix ; ( 2 ) localize basal cell squamous cell carcinoma skin ; ( 3 ) previous malignancy confine treat locally ( surgery modality ) curative intent . 8 . Uncontrolled systemic infection require parenteral antimicrobial therapy . 9 . Major surgery past 4 week . 10 . Known HIV , active hep B hep C infection ( detect positive PCR ) . 11 . Cardiovascular disease result New York Heart Association function status ≥ 3 . 12 . Significant active renal , neurologic , psychiatric , hepatic endocrinologic disease investigator 's opinion would adversely impact his/her participate study . 13 . Inability comply study procedure . 14 . On medication CYP3A inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>